Literature DB >> 29286050

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Giovanni Targher1, Amedeo Lonardo2, Christopher D Byrne3,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus are common diseases that often coexist and might act synergistically to increase the risk of hepatic and extra-hepatic clinical outcomes. NAFLD affects up to 70-80% of patients with type 2 diabetes mellitus and up to 30-40% of adults with type 1 diabetes mellitus. The coexistence of NAFLD and diabetes mellitus increases the risk of developing not only the more severe forms of NAFLD but also chronic vascular complications of diabetes mellitus. Indeed, substantial evidence links NAFLD with an increased risk of developing cardiovascular disease and other cardiac and arrhythmic complications in patients with type 1 diabetes mellitus or type 2 diabetes mellitus. NAFLD is also associated with an increased risk of developing microvascular diabetic complications, especially chronic kidney disease. This Review focuses on the strong association between NAFLD and the risk of chronic vascular complications in patients with type 1 diabetes mellitus or type 2 diabetes mellitus, thereby promoting an increased awareness of the extra-hepatic implications of this increasingly prevalent and burdensome liver disease. We also discuss the putative underlying mechanisms by which NAFLD contributes to vascular diseases, as well as the emerging role of changes in the gut microbiota (dysbiosis) in the pathogenesis of NAFLD and associated vascular diseases.

Entities:  

Mesh:

Year:  2017        PMID: 29286050     DOI: 10.1038/nrendo.2017.173

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  187 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  How to diagnose NAFLD in 2016.

Authors:  E Bugianesi; C Rosso; H Cortez-Pinto
Journal:  J Hepatol       Date:  2016-07-09       Impact factor: 25.083

Review 4.  Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.

Authors:  Guangqin Xiao; Sixian Zhu; Xiao Xiao; Lunan Yan; Jiayin Yang; Gang Wu
Journal:  Hepatology       Date:  2017-09-26       Impact factor: 17.425

Review 5.  The adipocyte as an active participant in energy balance and metabolism.

Authors:  Michael K Badman; Jeffrey S Flier
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

Review 6.  Diabetes and cardiovascular disease. The "common soil" hypothesis.

Authors:  M P Stern
Journal:  Diabetes       Date:  1995-04       Impact factor: 9.461

7.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

Review 8.  Diets and nonalcoholic fatty liver disease: the good and the bad.

Authors:  Mohamed Asrih; François R Jornayvaz
Journal:  Clin Nutr       Date:  2013-11-08       Impact factor: 7.324

9.  Lipid-induced hepatic insulin resistance.

Authors:  Thomas Galbo; Gerald I Shulman
Journal:  Aging (Albany NY)       Date:  2013-08       Impact factor: 5.682

Review 10.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069

View more
  76 in total

1.  Nonalcoholic Fatty Liver Disease and Bone Mineral Density in Children and Adolescents: Specific Considerations for Future Studies.

Authors:  Alessandro Mantovani
Journal:  Dig Dis Sci       Date:  2018-11-14       Impact factor: 3.199

2.  Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes.

Authors:  E Cipponeri; N Vitturi; V Mariano; F Boscari; S Galasso; C Crepaldi; G P Fadini; S Vigili de Kreutzenberg; M C Marescotti; E Iori; F Cavallin; L Sartori; A Baritussio; A Avogaro; D Bruttomesso
Journal:  J Endocrinol Invest       Date:  2019-03-07       Impact factor: 4.256

3.  Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus?

Authors:  Giovanni Targher
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 4.  The Potential Role of Fatty Acids in Treating Diabetic Neuropathy.

Authors:  Mark A Yorek
Journal:  Curr Diab Rep       Date:  2018-08-25       Impact factor: 4.810

Review 5.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

6.  Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease.

Authors:  Tatsuya Yamada; Daisuke Murata; Yoshihiro Adachi; Kie Itoh; Shoichiro Kameoka; Atsushi Igarashi; Takashi Kato; Yoichi Araki; Richard L Huganir; Ted M Dawson; Toru Yanagawa; Koji Okamoto; Miho Iijima; Hiromi Sesaki
Journal:  Cell Metab       Date:  2018-07-12       Impact factor: 27.287

Review 7.  The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.

Authors:  Cyrielle Caussy; Adrien Aubin; Rohit Loomba
Journal:  Curr Diab Rep       Date:  2021-03-19       Impact factor: 4.810

8.  Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes.

Authors:  Halima Fennoun; Souhaila El Mansouri; Mohammed Tahiri; Nassim Essabah Haraj; Siham El Aziz; Fouad Hadad; Wafaa Hliwa; Wafaa Badr; Asma Chadli
Journal:  Pan Afr Med J       Date:  2020-11-25

Review 9.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

10.  Risk of Typical Diabetes-Associated Complications in Different Clusters of Diabetic Patients: Analysis of Nine Risk Factors.

Authors:  Michael Leutner; Nils Haug; Luise Bellach; Elma Dervic; Alexander Kautzky; Peter Klimek; Alexandra Kautzky-Willer
Journal:  J Pers Med       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.